Is Medtronic (MDT) overvalued or fairly valued?

MarketChacha shows Medtronic's valuation in context — a trailing P/E of about 24.2, a forward P/E of about 14.8, a price-to-book of about 2.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Medtronic's reported profit turn into cash?

Over 4 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.61×) from reported figures — education, not a rating.

What is Medtronic's revenue?

Medtronic reported revenue of $36.4B for FY2026, with net profit of $4.8B, per official filings.

What is the share price of Medtronic (MDT)?

Medtronic last traded at $94.75 (-0.7% on the day), as of 10/16/2026 — a delayed quote shown for education, not investment advice.

Medtronic

MDT · NYSE · MedTech · United States

Snapshot

TickerMDT

ExchangeNYSE

SectorMedTech

IndustryMedical Devices

CountryUnited States

Employees95,000

HeadquartersGalway, Ireland

Websitewww.medtronic.com

Filings tracked17

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

Who owns it

Insiders0.3%
Institutions88.7%
Public & other11.0%

2,929 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.91%
Vanguard Capital Management LLC6.55%
State Street Corporation4.96%
Vanguard Portfolio Management LLC2.66%
Geode Capital Management, LLC2.36%
JPMORGAN CHASE & CO2.17%
Bank of America Corporation1.67%
Massachusetts Financial Services Co.1.55%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.61×

Over 4 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend12.0% → 13.2%

Margin has expanded by about 1.2 points — the business is getting more profitable.

Growth qualityrev 5% · PAT 9%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $9.5B · EPS 1.42

Est. earnings growth +4.7%

Next fiscal year

Rev $40.4B · EPS 6.41

Est. earnings growth +7.2%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2026)

$36.4B

Net margin

13.2%

ROE

9.7%

Revenue CAGR (3y)

+5.2%

Profit CAGR (3y)

+8.5%

EPS (FY2026)

3.73

Net profit (FY2026)

$4.8B

Ask MarketChacha about MDT

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2026	$36.4B	$4.8B	3.73	13.2%	9.7%
FY2025	$33.5B	$4.7B	3.61	13.9%	9.7%
FY2024	$32.4B	$3.7B	2.76	11.4%	7.3%
FY2023	$31.2B	$3.8B	2.82	12.0%	7.3%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q3	$9.8B	$1.5B	1.14	15.1%
2026Q1	$9.0B	$1.1B	0.89	12.7%
2025Q4	$9.0B	$1.4B	1.07	15.3%
2025Q3	$8.6B	$1.0B	0.81	12.1%
2025Q1	$8.3B	$1.3B	1.01	15.6%
2024Q4	$8.4B	$1.3B	0.99	15.1%
2024Q3	$7.9B	$1.0B	0.80	13.2%
2024Q1	$8.1B	$1.3B	0.99	16.3%
2023Q4	$8.0B	$909.0M	0.68	11.4%
2023Q3	$7.7B	$791.0M	0.59	10.3%
2023Q1	$7.7B	$1.2B	0.92	15.8%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC9/3/2026
8-K — Results of operations, Exhibits
SEC9/1/2026material
10-K filing
SEC6/18/2026
8-K — Results of operations, Exhibits
SEC6/3/2026material
8-K — Executive/director change, Exhibits
SEC5/18/2026material
8-K — Reg FD disclosure, Exhibits
SEC4/27/2026material
8-K — Reg FD disclosure
SEC3/24/2026material
10-Q filing
SEC2/24/2026
8-K — Results of operations, Exhibits
SEC2/17/2026material

2025

10-Q filing
SEC11/25/2025
8-K — Results of operations, Exhibits
SEC11/18/2025material
8-K — Executive/director change
SEC11/3/2025material
8-K — Bylaw/charter change, Shareholder vote results, Exhibits
SEC10/21/2025material
8-K — Material agreement, Other events, Exhibits
SEC9/29/2025material
8-K — Reg FD disclosure, Other events, Exhibits
SEC9/16/2025material
10-Q filing
SEC8/26/2025
8-K — Results of operations, Executive/director change, Exhibits
SEC8/19/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.